Wegovy's new higher dose: what the 7.2mg approval means in practice

You've heard 7.2mg exists, here's the detail you actually need

Picture this: you've been on Wegovy for several months, you're responding well, and someone mentions a higher dose has been approved. You search, find fragments of news, and want to know what it actually means before your next prescriber check-in. That's precisely where most people land, and the facts are worth laying out clearly.

Until January 2026, 2.4mg was the top of Wegovy's licensed ladder in the UK. The MHRA then authorised 7.2mg as a new maintenance dose, initially supplied as three 2.4mg pens administered in the same week. The practical difficulty there was obvious. The April 2026 approval of the dedicated single-dose pen resolved it: one pen, one injection, once a week. The pen has an auto-dosing mechanism and a built-in covered needle that locks after use, which removes the dose-setting step. The full Wegovy dose schedule still starts at 0.25mg; the only thing that changed is where the ladder now ends.

It is also worth being clear about what the 7.2mg approval does not do. It does not lower the BMI threshold, this dose is licensed for adults with a BMI of 30 or above only, not for the 27–29.9 range that the 2.4mg maintenance dose can cover alongside a weight-related condition. Your prescriber decides whether you are a candidate, based on your progress and overall health picture, and if you want a closer look at what the new Wegovy dose involves, that detail is worth reviewing before your next check-in.

What the trial evidence showed, and how to read the numbers honestly

Trial data for the 7.2mg dose reported around 20.7% average weight loss over 72 weeks. That is a meaningful step up from the roughly 15% average seen with 2.4mg in the STEP 1 trial, which the New England Journal of Medicine published in 2021. The 7.2mg figure also starts to approach what tirzepatide achieves at its highest dose, something that matters for people comparing their options when treatment at 2.4mg has plateaued.

A few things to hold alongside those numbers. Trial participants follow strictly controlled conditions with lifestyle support built in; real-world results vary. Averages mask a wide spread, some people lose considerably more, some less. And the 20.7% figure comes from the period that led to the approval, not from a head-to-head trial comparing the two Wegovy doses directly. What it tells you is that the higher dose produced greater weight loss in the population studied. Whether you personally would respond differently at 7.2mg is a question your prescriber can engage with, not one a headline can answer. You can read the MHRA's announcement of the 7.2mg pen approval for the official statement.

For context on how Wegovy sits alongside other higher-dose semaglutide options, it helps to understand that semaglutide works through a single GLP-1 receptor pathway, whereas tirzepatide acts on two pathways simultaneously. The gap between the medicines narrows at 7.2mg, but a prescriber weighing both options looks at your full health picture, not just efficacy figures in isolation.

Does this change your current prescription, or your ability to start treatment?

If you are already on Wegovy, nothing changes automatically. Your prescription stays as it is until your prescriber reviews it. That review might happen at your next check-in, or you might want to raise it sooner, either way, the right route is through your clinical team, not by adjusting your dose independently. The Patient Information Leaflet and your prescriber are the definitive sources for any changes to your individual treatment. Specific availability of the 7.2mg pen format is confirmed at consultation, as stock position varies.

If you are considering starting Wegovy for the first time, the approval of a higher dose does not change the entry point. Treatment still begins at 0.25mg. Think of the earlier doses as the period when your body adapts, the gastrointestinal side effects that some people notice at the start (nausea, loose stools, reduced appetite that can feel uncomfortable rather than welcome) tend to settle as the body adjusts. Rushing to higher doses makes those effects more likely, which is why the graduated schedule exists. You can explore why starting at a higher dose is not recommended if that question is on your mind.

For those keeping an eye on what Wegovy costs privately, pricing for specific doses is confirmed at consultation, and that single transparent price at nume covers the consultation, prescription, and next-working-day tracked delivery, with no subscription and no hidden charges. If you're placing an order before noon on a weekday, dispatch happens the same day once your prescriber approves it, which fits neatly around the school-run rush for anyone managing the logistics of treatment at home.

The broader weight-loss treatment landscape now includes more options than it did even two years ago, and our clinical team stays current with all of them. If you'd like to talk through whether Wegovy is right for you, or what the new dose might mean for your treatment, a free consultation is the place to start.

Check your eligibility with a free consultation, reviewed by a GPhC-registered prescriber, the same day you apply.